• 1
    Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Cancer. 2004; 100: 44-52.
  • 2
    Chia SK, Speers CH, D'yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007; 110: 973-979.
  • 3
    Abrial C, Leheurteur M, Cabrespine A, et al. Does survival increase in metastatic breast cancer with recently available anticancer drugs? Oncol Res. 2006; 15: 431-439.
  • 4
    Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst. 2006; 98: 1285-1291.
  • 5
    Brodie A, Lu Q, Long B. Aromatase and its inhibitors. J Steroid Biochem Mol Biol. 1999; 69: 205-210.
  • 6
    Miki Y, Suzuki T, Hatori M, et al. Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: a possible androgenic bone protective effects induced by exemestane. Bone. 2007; 40: 876-887.
  • 7
    Lonning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol. 2000; 18: 2234-2244.
  • 8
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
  • 9
    Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975; 31: 103-115.
  • 10
    National Cancer Institute, National Institutes of Health, Department of Health and Human Services. Common Toxicity Criteria Manual, version 2.0. Bethesda, MD: National Cancer Institute; 1999.
  • 11
    Rose C, Vtoraya O, Pluzanska A, et al. An open randomized trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer. 2003; 39: 2318-2327.
  • 12
    Campos SM, Guastalla JP, Subar M, et al. A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer. 2009; 9: 39-44.
  • 13
    Goss P, von Eichel L. Summary of aromatase inhibitor trials: the past and future. J Steroid Biochem Mol Biol. 2007; 106: 40-48.
  • 14
    Goss PE, Ingle JN, Chapman J-AW, et al. Final analysis of NCIC CTG MA. 27: a randomized phase III trial of exemestane versus anastrozole in postmenopausal women with hormone receptor positive primary breast cancer [abstract]. Paper presented at: 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, Tex. Abstract S1-1.
  • 15
    Iaffaioli RV, Formato R, Tortoriello A, et al. Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. Br J Cancer. 2005; 92: 1621-1625.
  • 16
    Gennatas C, Michalaki V, Carvounis E, et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO). Tumori. 2006; 92: 13-17.
  • 17
    Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008; 26: 1664-1670.
  • 18
    Bertelli G, Garrone O, Merlano M, et al. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology. 2005; 69: 471-477.
  • 19
    Santen RJ, Song RX, Zhang Z, et al. Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer. Clin Cancer Res. 2004; 10: 337s-345s.
  • 20
    Lonning PE. Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? Eur J Cancer. 2009; 45: 527-535.
  • 21
    Geisler J, Helle H, Ekse D, et al. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin Cancer Res. 2008; 14: 6330-6335.